Clinical and Economic Case for Pre-op Skin Prepping - PowerPoint PPT Presentation

1 / 13
About This Presentation
Title:

Clinical and Economic Case for Pre-op Skin Prepping

Description:

This may partially be explained by the emergence of antimicrobial-resistant ... as having 'excellent' activity against gram-positive bacteria (i.e., MRSA) as ... – PowerPoint PPT presentation

Number of Views:38
Avg rating:3.0/5.0
Slides: 14
Provided by: karinhopp
Category:

less

Transcript and Presenter's Notes

Title: Clinical and Economic Case for Pre-op Skin Prepping


1
(No Transcript)
2
Postoperative SSIs
  • Magnitude of Problem
  • Despite advances in infection control practices,
    SSIs remain a substantial cause of morbidity and
    mortality among hospitalized patients. This may
    partially be explained by the emergence of
    antimicrobial-resistant pathogens and the
    increased numbers of surgical patients who are
    elderly and/or have a wide variety of chronic,
    debilitating, or immunocompromising underlying
    diseases.

Mangram AJ, et al., Guideline for prevention of
surgical site infection, 1999. Centers for
Disease Control and Prevention, Hospital
Infection Control Practices Advisory Committee,
Atlanta GA
3
Postoperative SSIs
  • Magnitude of Problem
  • Approximately 60 million surgical procedures
    performed per year in the U.S.1,2
  • 2.6 to 5 of surgical procedures result in
    surgical site infections (SSIs) 3,4
  • At least 1.5 million SSIs per year in the U.S.5
  • 1. DeFrances CJ, Hall MJ, Podgornik MN, 2003
    National hospital discharge survey. CDC, National
    Center for Health Statistics, Advance Data from
    Vital and Health Statistics. No. 3598 July
    200514.
  • 2. Hall MJ, Lawrence L, Ambulatory surgery in the
    United States, 1996. CDC, National Center for
    Health Statistics, Advance Data from Vital and
    Health Statistics. No. 30012 Aug 19987.
  • 3. Mangram AJ, et al., Guideline for prevention
    of surgical site infection, 1999. Centers for
    Disease Control and Prevention, Hospital
    Infection Control Practices Advisory Committee,
    Atlanta GA.
  • 4. Institute for Healthcare Improvement (IHI),
    Topics patient safety surgical site infections
    case for improvement. (accessed 16 Jan 2006 at
    http//www.ihi.org).
  • 5. Figure calculated by multiplying SSI rate from
    ref. 3 by surgical procedure numbers from ref.
    1 and 2.

4
Surgical Site Infections
  • The leading hospital-acquired infection for
    surgicalpatients (38)1
  • The third most common hospital-acquiredinfection
    overall 1
  • Patients who develop are twice as likely to die
    and 60 more likely to spend time in the ICU 2
  • Increase hospital length of stay by 7 to 10 days
    1
  • Account for more than 25,000 increase
    inhospital costs 3
  • One of the two most expensive infectionsto
    healthcare 3

1. Mangram AJ, et al., Guideline for prevention
of surgical site infection, 1999. Centers for
Disease Control and Prevention, Hospital
Infection Control Practices Advisory Committee,
Atlanta GA. 2. Kirkland KB, et al., Infect
Control Hosp Epidemiol. Nov 199920(11)722-4. 3.
Stone PW, et al., Am J Infect Control. Nov
200533(9)501-9
5
Goal Address a Known Risk Factor for SSIs
  • Reduce themicroorganismson the patients skin.
  • We should initiate acomprehensive approachfor
    skin antisepsis.

6
Current Practice
  • Our current practice
  • We have a protocol?
  • The protocol is aligned with CDC guidelines for
    preventing SSIs?
  • Compliance to protocol is?
  • Hospital / surgeon compliance level?
  • Patient compliance level?

7
Where we want to be
  • Establish multidisciplinary SSI prevention team
  • Increased awareness
  • Standardized pre-op prep protocol aligned with
    CDC guidelines for preventing SSIs
  • High compliance to protocol
  • Hospital / surgeon compliance gt90
  • Patient compliance gt80

8
Solution
  • Pre-op skin prepping with CHG
  • CHG is persistent, active for up to 6 hours
  • Literature suggests that repeat applications
    maximize antimicrobial effect
  • Rapid bactericidal action
  • The only pre-op skin prep agent that the CDC
    recognizes as having excellent activity against
    gram-positive bacteria (i.e., MRSA) as well as
    excellent residual activity

9
Solution
  • Pre-op skin prepping with Sage 2 CHG
  • Only FDA-Approved cloth delivery of CHG
  • Unique 2 CHG formulation Fast-acting and
    broad spectrum Persistent Free of alcohol
    and harsh detergents
  • Unique one-step applicator cloth Delivers a
    uniform dose of CHG No drips, runs or
    pooling Large cloth allows easy prepping of
    body contours

10
Implementation
11
Awareness
  • Announcement Letter

Posters
12
How Sage 2 CHG Works
13
Thank Youfor your time!
Write a Comment
User Comments (0)
About PowerShow.com